SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing robust vehicle deliveries for December and the fourth quarter, reaching new highs and demonstrating significant annual growth. The community is actively discussing the potential for imminent profitability, buoyed by strong sales performance and recently extended government subsidies favoring NEVs, positioning NIO ahead of its Chinese counterparts. Despite positive operational momentum, many investors are capitalizing on price dips, anticipating a strong market response as the company's fundamentals continue to improve.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

The Dogecoin community is abuzz with divided sentiment, as year-end activities like tax loss selling appear to be influencing recent price action. While some express frustration over current levels, a resilient cohort of investors anticipates a strong rebound and potential rallies in the coming year, fueled by hopes for future market cycles. The ongoing debate centers on whether this period marks a prime accumulation opportunity or a signal for further caution.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to its strategic sale of Bressner Technology, which has boosted its cash reserves and sharpened its focus on core AI and edge computing. The community is actively discussing the company's recent stronger-than-expected earnings and raised guidance, alongside high anticipation for a significant military contract for 360 situational awareness systems. Many investors view OSS as an undervalued pure-play in the growing Edge AI and defense sectors, highlighting its tight float and institutional interest.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid intense frustration as the biotech sector's (XBI) extended bullish rally continues to defy expectations, leading to significant pressure on this 3x leveraged bear ETF. The community is sharply divided, with many anticipating an imminent, overdue reversal due to XBI's stretched technicals and high RSI, while others caution against fighting the sector's persistent upward momentum.

Power & Digital Infrastructure Acquisition Corp. operates as a blank check company. The firm engages in seeking a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on December 29, 2020 and is headquartered in Chicago, IL.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific is drawing significant attention after its shareholders rejected a merger offer from CoreWeave, leading to mixed community sentiment on its valuation as an AI/HPC infrastructure provider. Enthusiasm for its substantial power capacity and potential for new high-performance compute lease agreements is tempered by investor frustration over perceived operational delays and a lack of timely updates.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is trending as investors weigh its full-year vehicle delivery growth, which more than doubled despite missing some recent quarterly guidance, against intense competition in the Chinese EV sector. The community is actively discussing newly extended government subsidies for electric vehicles into 2026 and the company's aggressive global expansion, including new market entries and local production initiatives. Despite recent volatility and comparisons to rivals, many believe the stock is undervalued, highlighting its advancements in AI, robotics, and autonomous driving capabilities as key future drivers.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following the FDA's acceptance of its sNDA for AXS-05 in Alzheimer's disease agitation with Priority Review, setting a PDUFA target in April 2026. This significant regulatory clarity, coupled with positive updates for AXS-12 in narcolepsy and continued strong Auvelity script growth, is fueling widespread optimism among investors. The community is celebrating substantial long-term gains and actively discussing AXSM's potential to become a major CNS powerhouse, anticipating further analyst upgrades and robust performance as the company advances its diverse pipeline and commercial footprint.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix Corp (ENVX) is trending amid mixed sentiment following a recent fireside chat that updated investors on battery testing timelines for smartphones and smart eyewear, ahead of its anticipated presence at CES. While many remain confident in the long-term potential of its silicon-anode technology, others express deep frustration over repeated commercialization delays and perceived management underperformance in a competitive battery market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock, Marketbeat.com...

Exchange Traded Concepts LLC Has $912,000 Position in Terns Pharmaceuticals, Inc. $TERN

Exchange Traded Concepts LLC reduced its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 46.7% during the 3rd quarter, according to the company in its most recent 13F filing...

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 62,525 Shares of Terns Pharmaceuticals, Inc. $TERN

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 18.6% in the second quarter, according...

Terns Pharmaceuticals (NASDAQ:TERN) Price Target Raised to $57.00

Citizens Jmp boosted their price objective on Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a "market outperform" rating in a report on Thursday...

Research Analysts Set Expectations for TERN FY2027 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for shares of Terns Pharmaceuticals in a research note...

Pharmaceutical Stocks To Follow Today - December 10th

Eli Lilly and Company, AbbVie, Pfizer, Novo Nordisk A/S, and Terns Pharmaceuticals are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical...

Terns Pharmaceuticals (NASDAQ:TERN) Sees Large Volume Increase - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Sees Large Volume Increase - Still a Buy...

<ul class="summary-bullets"><li>Terns shares jumped after new Phase 1 data showed strong response rates and a continued favorable safety profile for TERN-701.</li><li>Updated results showed high 24-week molecular responses across doses with no loss of response and no dose-limiting toxicities.</li><li>The company said the findings support Phase 2 advancement, with deep responses seen even in patients previously failing multiple therapies.</li></ul>Terns Pharmaceuticals (TERN) shares jumped over 40% on Monday after the company reported additional positive Phase 1 results for its investigational chronic myeloid leukemia (CML) therapy TERN-701 at the 67th American Society of Hematology Annual Meeting.The biotech company said updated data from the ongoing CARDINAL trial showed a 64% major molecular response (MMR) rate by 24 weeks across all efficacy-evaluable patients, with a 75% MMR rate among those receiving doses above 320 mg once daily.&nbsp;The company said the treatment continued to show an encouraging safety and tolerability profile with longer exposure.<h2 class="st-heading-2">Terns Sets Phase 2 Doses&nbsp;</h2>CEO Amy Burroughs said the higher MMR rate at doses of 320 mg and 500 mg supports selection of those levels as recommended Phase 2 doses. She said study enrollment has surpassed 85 patients, enabling further progression into dose-expansion and pivotal studies.Chief Medical Officer Emil Kuriakose said the data include response achievements in patients who had previously experienced lack of efficacy on drugs such as Asciminib, Ponatinib and other tyrosine kinase inhibitors. He said the updated findings show deep molecular responses (DMR) at 24 weeks and a continued favorable safety profile across doses.<h2 class="st-heading-2">Strong 24-Week Response Rates</h2>As of the Sept. 13 cutoff, 63 patients had been enrolled across doses ranging from 160 mg to 500 mg. Among 38 efficacy-evaluable patients, the overall MMR rate by 24 weeks was 74%. No patients had lost MMR at the time of analysis.The company said the study population reflected heavily pretreated, refractory disease, including a median of three prior tyrosine kinase inhibitors (TKIs) and high rates of lack of efficacy to previous therapy.Safety data showed that 87% of patients remained on treatment, with no dose-limiting toxicities observed and no maximum tolerated dose reached. Most treatment-emergent adverse events were low grade, and rates of cytopenias were generally under 10%.<h2 class="st-heading-2">Responses At Higher Doses</h2>Among patients treated at doses of 320 mg or higher, the company reported an 80% overall MMR rate by 24 weeks in the efficacy-evaluable population. Deep molecular responses were observed across a wide range of baseline transcript levels.<h2 class="st-heading-2">Stocktwits Traders Cheer Momentum</h2>On Stocktwits, retail sentiment for Terns was ‘bullish’ amid ‘low’ message volume.<figure class="image"><img style="aspect-ratio:984/147;" src="https://news.stocktwits-cdn.com/terns_ss_png_43b9b42eb3.webp" alt="terns ss.png" width="984" height="147"><figcaption>TERN sentiment and message volume as of December 8| Source: Stocktwits</figcaption></figure>One user said, “congrats!&nbsp; Bio market is starting to have some movers. Good to see!”<stembedurl>https://stocktwits.com/Hard6and8/message/638531110</stembedurl>Another user urged investors to “buy it up.”<stembedurl>https://stocktwits.com/Whiskeyunderthebed/message/638530725</stembedurl><a href="https://stocktwits.com/symbol/TERN">Tern’s stock</a> has surged 620% so far this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tern's stock (TERN) has surged 489% so far in 2025. (Photo credit: Getty Images)

Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients

New Phase 1 data showed strong response rates and a favorable safety profile for its experimental leukemia drug TERN-701.

Equity

Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Time to Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Should You Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 5.5% - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 5.5% - Still a Buy...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.30	--	--	N/A
Q3 '25	-$0.30	-$0.27	9.02%	BEAT
Q2 '25	-$0.29	-$0.26	10.45%	BEAT
Q1 '25	-$0.29	-$0.26	11.54%	BEAT
Q4 '24	-$0.31	-$0.24	21.61%	BEAT

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TERN News

TERNTerns Pharmaceuticals Inc